Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series

Brown, Malcolm; O’Connor, Dominic; Turkington, Richard; Eatock, Martin; Vince, Rebecca; Hulme, Claire; Bowdery, Roy; Robinson, Rebecca; Wadsley, Jonathan; Maraveyas, Anthony; Prue, Gillian

doi:10.1186/s13102-023-00722-3

BMC Sports Science, Medicine and Rehabilitation

Table 3 Outcome measures

From: Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series

	Participant 1			Participant 2						Participant 4			Participant 5
	Base	Post	3-M	Base	Post	3-M	Base	Post	3-M	Base	Post	3-M	Base	Post	3-M
Mass (kg)	69.2	75.2	79.7	58.6	DNA	64.3	79	82.1	83.5	79.5	74.7	76.6	71.4	72	72.4
BMI (kg/m²)	24.8	26.9	28.5	22.6	DNA	24.8	26	27.1	27.5	23.6	22.2	22.7	24.4	24.4	24.7
Hip (cm)	91	104	100	97	DNA	99	97	102	104.5	99	95.5	95	98	95	95
Waist (cm)	85.5	97	97	82	DNA	86	93	99	103	95	94.5	93	89.5	88	86
6-min walk (m)	270	300	320	140	DNA	160	506	549	615	447	523	480	500	560	590
Timed sit to stand (reps)	10	13	12	8	DNA	8	15	15	14	13	13	13	12	16	20
Chest press 1RM (kg)	38	45	52	Om	DNA	Om	61	70	72	Om	Om	Om	52	58	61
Seated row 1RM (kg)	43	65	75	Om	DNA	Om	61	82	93	Om	Om	Om	65	80	79
Leg press 1RM (kg)	Om	Om	Om	Om	DNA	Om	96	123	160	Om	Om	Om	Om	Om	Om
Leg extension 1RM (kg)	45.5	65	79	Om	DNA	Om	Om	Om	Om	Om	Om	Om	107	131	116
FACT-G Physical Social Emotional Functional FACT-Hep	94 27 26 24 17 159	101 25 28 24 24 167	85 22 25 22 16 141	34 2 20 6 6 60	DNA DNA DNA DNA DNA DNA	48 8 28 7 5 90	86 25 24 21 16 152	73 23 20 20 10 136	101 25 26 22 28 169	108 28 28 24 28 175	100 22 28 24 26 162	98 22 24 24 28 164	102 23 28 23 28 169	104 26 28 22 28 175	107 27 28 24 28 179
FACIT-Fatigue	42	47	32	11	DNA	5	47	36	48	48	20	30	45	49	52
BPI
Severity Interference	0 0	2.75 0.57	1.5 1	4 6.86	DNA DNA	4.25 8	1.75 0.57	0 0	0 0	0 0	0 0.3	2.5 0	0 0	0 0	0 0
EQ-5D-5 L
Health state VAS	11,222 90	11,122 75	33,332 70	22,433 50	DNA DNA	43,444 25	11,111 70	11,111 80	11,111 95	11,111 85	21,111 90	11,121 90	11,111 90	11,111 90	11,111 100
IPAQ
Vigorous (d•wk^− 1) Time (min•day^− 1) Moderate (d•wk^− 1) Time (min•day^− 1) Walking (d•wk^− 1) Time (min•day^− 1) Sitting (h•day^− 1)	0 - 0 - 7 Unsure 3	3 60 2 120 7 60 6	0 - 0 - 4 30 8	0 - 0 - 1 10 7	DNA DNA DNA DNA DNA DNA DNA	0 - 0 - 0 - 12	0 - 0 - 5 60 8	2 90 0 - 2 30 9	0 - 0 - 5 60 5	0 - 7 120 2 30 6	1 20 5 20 4 30 5	0 - 1 20 4 30 6	1 120 1 180 2 20 4	2 45 4 60 7 60 4	2 60 1 360 2 60 8

Abbreviations: Base, baseline; BMI, body mass index; BPI, brief pain inventory; d•wk^− 1, days per week; DNA, did not attend; EQ-5D-5L, EuroQol 5 dimensions 5 levels; FACT-G, functional assessment of cancer therapy - general; FACT-Hep, functional assessment of cancer therapy – hepatobiliary; IPAQ, International Physical Activity Questionnaire; post, post-intervention; min•day^− 1, mins per day; Om, omitted; 3-M, 3-month follow up; 1RM, 1-repetition maximum. 1RM testing: Participants completed 1 out of 2 leg exercises based on preference, not both. Participant 2 1RM testing omitted due to frailty; participant 4 1RM omitted due to out of hours attendance for outcomes.

Back to article page

ISSN: 2052-1847

Contact us

General enquiries: journalsubmissions@springernature.com